About Montes Archimedes Acquisition Corp
Montes Archimedes Acquisition Corp. focuses to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was founded in 2020 and is based in Menlo Park, California. Address: 724 Oak Grove, Menlo Park, CA, United States, 94025
Montes Archimedes Acquisition Corp News and around…
Latest news about Montes Archimedes Acquisition Corp (MAACU) common stock and company :
If you want to know who really controls Montes Archimedes Acquisition Corp. ( NASDAQ:MAAC ), then you'll have to look...
Roivant will begin trading on Nasdaq under the ticker “ROIV” later todayR&D Day presentations from September 28th highlighting Roivant’s pipeline and discovery platform available on Roivant’s investor page BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Roivant Sciences, a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it has closed its business combination with Montes Archimedes Acquisition C
Roivant Sciences today announced that Datavant, the leader in helping healthcare organizations securely connect their data, and Ciox Health, the leader in clinical data exchange, have signed a definitive merger agreement.
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Montes Archimedes Acquisition Corp. ("MAAC" or the "Company") (MAAC) relating to its proposed merger with Roivant Sciences. Under the terms of the agreement, MAAC will acquire Roivant through a reverse merger, with Roivant emerging as a publicly traded company.
BALA CYNWYD, PA / ACCESSWIRE / May 3, 2021 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Montes Archimedes Acquisition Corp. ("Montes Archimedes " or the "Company") (NASDAQ:MAAC) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which Montes Archimedes, a special purpose acquisition company, will combine with Roivant Sciences, a biopharmaceutical and healthcare technology company, and result in Roivant Sciences becoming a publicly-listed company.
Roivant Sciences, a biopharmaceutical and healthcare technology company, and Montes Archimedes Acquisition Corp. (Nasdaq: MAAC), a special purpose acquisition company sponsored by Patient Square Capital, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, outstanding shares and warrants of MAAC will be exchanged for newly issued shares and warrants of Roivant Sciences, which is expected to be listed on Nasdaq under the new ticker symbol "ROIV."
Every investor in Montes Archimedes Acquisition Corp. ( NASDAQ:MAAC ) should be aware of the most powerful shareholder...
Montes Archimedes Acquisition Corp. (Nasdaq: MAACU) (the "Company") announced that, commencing November 27, 2020, holders of the units sold in the Company's initial public offering of 41,071,823 units, completed on October 9, 2020, may elect to separately trade the shares of Class A common stock and warrants included in the units. Those units not separated will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "MAACU," and the shares of Class A common stock and warrants that are separated will trade on Nasdaq under the symbols "MAAC" and "MAACW," respectively. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into shares of Class A common stock and warrants.